Racura Oncology

Why Invest

Updates

Announcements

Home

Inter

Racura Oncology InvestorHub

The Australian reports that The US Food and Drug Authority (FDA) has extended Rare Paediatric Disease Designation (RPDD) to Race’s oncology drug RC220 bisantrene for paediatric acute myeloid leukemia (AML). The RPDD in paediatric AML may qualify Race to be eligible for a Priority Review Voucher (PRV).

Race’s Executive Director, Dr Peter Smith, explains in an interview what the RPDD is and why is it a significant step forward for Race’s paediatric AML program.

Watch the Dr Smith's interview below. The full report is available here.

The Australian: Race Oncology Stock Gains On US FDA Milestone